NWBO and clinicians had no reason to unblind recurrent patients. They had all signed an informed consent for a NAIVE GBM trial (the original protocol) and that protocol specified that EVERY patient that had recurrence would be offered a rescue treatment.
Here's the clinicaltrials.gov: "All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain)"
Otherwise they would drop out of the trial. There is NO need to unblind patients at anytime in this trial.
Market Data 
Markets 
AI
